An interventional study of Low calorie meal replacement plan and Diabetes self management education in Type 2 Diabetes, sponsored by LMC Diabetes & Endocrinology Ltd.. Not yet recruiting at 6 sites in Canada. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by LMC Diabetes & Endocrinology Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · LMC Diabetes & Endocrinology Ltd..
Among the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., this one is one of 3 that started in 2025, is one of 4 with no phase, and was the 12th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. are open now, in 1 country. Recruiting first, the newest first:
LMC Diabetes & Endocrinology Ltd. · Sites in Canada
Ages 18+
LMC Diabetes & Endocrinology Ltd. · Sites in Canada
Ages 18+
LMC Diabetes & Endocrinology Ltd. · Sites in Canada
Ages 18–80
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 176 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 158 across the 6 interventional studies, 892 across the 8 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
LMC Diabetes & Endocrinology Ltd. is the lead sponsor of 22 studies on the registry; 4 are open to participants now.
2 of the studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07889453LMC Diabetes & Endocrinology Ltd.Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide | 2026-12 |
| NCT07157384LMC Diabetes & Endocrinology Ltd.REMIssion of Type 2 Diabetes Between Intermittently Scanned Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring When Added to Low-calorie Meal Replacement and Diabetes Self-management Education | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the study is to evaluate the effectiveness of intermittently scanned continuous glucose monitoring compared to capillary blood glucose monitoring among people with type 2 diabetes initiating low calorie meal replacement plus diabetes self-management education in improving the proportion of patients achieving remission of type 2 diabetes. This is an open-label randomized controlled trial with 2 treatment arms randomized in a 1:1 manner.
The Investigators hypothesize that the use of intermittently scanned continuous glucose monitoring will improve the percentage of participants achieving remission of type 2 diabetes (remission to prediabetes or remission to normoglycemia), among adults with type 2 diabetes starting low calorie meal replacement and diabetes self-management education compared to a control group using capillary blood glucose monitoring at 18-30 weeks follow-up (end of Phase 2).
The primary outcome of the study is to compare the percentage of participants who achieve remission of type 2 diabetes (remission to prediabetes with HbA1c 6.0% to 6.4% or remission to normoglycemia with HbA1c \< 6.0% using no antihyperglycemic agents for ≥ 3 consecutive months) at 18-30 weeks follow-up between intermittently scanned continuous glucose monitoring vs. capillary blood glucose monitoring, when combined with low calorie meal replacement and diabetes self-management education.
Participants in both arms complete 3 phases of the study. Phase 1: total dietary replacement, Phase 2: food re-introduction and Phase 3: remission, while receiving diabetes self-management education sessions over a span of 18 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group using an intermittently scanned continuous glucose monitor and receiving low calorie meal replacement and diabetes self management education
Dietary Supplement: Low calorie meal replacement plan · Behavioral: Diabetes self management education · Device: Intermittently scanned continuous glucose monitoring
Group using a capillary blood glucose monitor and receiving low calorie meal replacement and diabetes self management education
Dietary Supplement: Low calorie meal replacement plan · Behavioral: Diabetes self management education · Device: capillary blood glucose monitoring
intervention provided to both arms in 2 out of the 3 study phases: Phase 1 (total dietary replacement) and Phase 2 (food re-introduction)
intervention provided to both arms throughout study conducted as in-person session and telephone sessions
intervention provided to the intervention arm only: isCGM + LCMR + DSME
intervention provided to the control arm only: CBG + LCMR + DSME
Percentage of participants who achieve remission at the end of phase 2
The primary objective is to compare the percentage of participants who achieve remission of T2D (remission to prediabetes with HbA1c 6.0% to 6.4% or remission to normoglycemia with HbA1c \< 6.0%) using no antihyperglycemic agents for ≥ 3 consecutive months at 18-30 weeks follow-up between isCGM vs. CBG monitoring, when combined with LCMR and DSME
Time frame: from enrollment to end of phase 2 (18-30 weeks)
Proportion of participants achieving remission at the end of phase 1
Evaluating the proportion of participants achieving remission of T2D (remission to prediabetes with HbA1c 6.0% to 6.4% or remission to normoglycemia with HbA1c \< 6.0%) using no antihyperglycemic agents for ≥ 3 consecutive months at 12-24 weeks follow-up between intervention and control (isCGM vs. CBG monitoring, when combined with LCMR and DSME)
Time frame: from enrollment to end of phase 1 (12-24 weeks)
Proportion of participants achieving remission to prediabetes at the end of phase 1
Evaluating the proportion of participants between intervention and control groups achieving remission to prediabetes (HbA1c 6.0% to 6.4%) using no antihyperglycemic agents for ≥ 3 consecutive months at weeks 12-24 weeks follow-up
Time frame: from enrollment to end of phase 1 (12-24 weeks)
Proportion of participants achieving remission to normoglycemia at the end of phase 1
Evaluating the proportion of participants between the intervention and control group achieving remission to normoglycemia (HbA1c \< 6.0%) using no antihyperglycemic agents for ≥ 3 consecutive months at weeks 12-24 weeks follow-up
Time frame: from enrollment to end of phase 1 (12-24 weeks)
Follow-up and change in HbA1c for the participants who did not initiate/reinitiate antihyperglycemic agents at the end of Phase 1
comparing between intervention and control (isCGM vs. CBG monitoring, when combined with LCMR and DSME) the follow-up HbA1c (%) and the change in HbA1c (%) at the end of Phase 1 (12-24 weeks) for participants who did not initiate/reinitiate antihyperglycemic agents
Time frame: from enrollment to end of Phase 1 (12-24 weeks)
Adherence to low calorie meal replacement at the end of phase 1
Comparing the adherence to low calorie meal replacement (LCMR), defined as a score of 3, 4 or 5 out of 5 for LCMR adherence measured using the adherence questionnaire between the intervention and the control group at the end of phase 1 (12-24 weeks). A higher score on the scale indicates better adherence.
Time frame: from enrollment to end of Phase 1 (12-24 weeks)
Percentage relapse at the end of Phase 1
comparing the number of participants between intervention and control group that relapse during Phase 1, reported as a percentage. Relapse is defined as weight gain \> 2 kg from baseline body weight, HbA1c \> 9%, fasting glucose \> 11 mmol/L (on consecutive days, after first 4 weeks of LCMR), completely abandoning LCMR, and/or if participant needs to restart medications to lower their blood sugar (based on the doctor's recommendations).
Time frame: from enrollment to end of Phase 1 (12-24 weeks)
Time spent in Phase 1
Comparing the time spent in Phase 1 (12-24 weeks) between intervention and control group. Time spent will be measured in weeks
Time frame: from enrollment to end of phase 1 (12-24 weeks)
Proportion of participants achieving remission to prediabetes at the end of phase 2
Evaluating the proportion of participants between intervention and control groups achieving remission to prediabetes (HbA1c 6.0% to 6.4%) using no antihyperglycemic agents for ≥ 3 consecutive months at 18-30 weeks follow-up
Time frame: from enrollment to end of phase 2 (18-30 weeks)
Proportion of participants achieving remission to normoglycemia at the end of phase 2
Evaluating the proportion of participants between the intervention and control group achieving remission to normoglycemia (HbA1c \< 6.0%) using no antihyperglycemic agents for ≥ 3 consecutive months at weeks 18-30 weeks follow-up
Time frame: from enrollment to end of phase 2 (18-30 weeks)
Follow-up and change of scores for Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) scale at the end of phase 2
Evaluating the follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) scale between the intervention and control group at the end of phase 2 ( 18-30 weeks). The DTSQs scale has 8 questions measured on a Likert scale from 6 (very satisfied) to 0 (very dissatisfied) about the participants satisfaction with their diabetes treatment in the last few weeks.
Time frame: from enrollment to end of phase 2 (18-30 weeks)
Follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) scale at the end of phase 2
Evaluating the follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) scale between the intervention and control group at the end of phase 2 (18-30 weeks). The DTSQc scale has 8 questions measured on a Likert scale from 3 (much more satisfied now) to -3 (much less satisfied now) about the participants satisfaction of their diabetes treatment in the past 4-7 months.
Time frame: from enrollment to end of phase 2 (18-30 weeks)
Follow-up and change of scores in the Diabetes Distress scale (DDS) at the end of phase 2
Evaluating the follow-up and change in scores in the Diabetes Distress scale (DDS) at the end of phase 2 (18-30 weeks) between intervention and control group. The DSS includes 17 questions measured on a Likert scale from 1 (not a problem) to 6 (a very serious problem) about the degree that diabetes has caused the participant distress in the past month. A higher score is reflective of more distress.
Time frame: from enrollment to end of phase 2 (18-30 weeks)
Proportion of participants achieving remission of T2D at the end of phase 3
Evaluating the proportion of participants who achieve remission of T2D (remission to prediabetes with HbA1c 6.0% to 6.4% or remission to normoglycemia with HbA1c \< 6.0% using no antihyperglycemic agents for ≥ 3 consecutive months) at 30-44 weeks follow-up between intervention and control ( isCGM vs. CBG monitoring, when combined with LCMR and DSME)
Time frame: from enrollment to end of phase 3 (30-44 weeks)
Proportion of participants achieving remission to prediabetes at the end of phase 3
Evaluating the proportion of participants achieving remission to prediabetes (HbA1c 6.0% to 6.4% using no antihyperglycemic agents for ≥ 3 consecutive months) at 30-44 weeks between intervention and control group (isCGM vs. CBG monitoring, when combined with LCMR and DSME)
Time frame: from enrollment to end of phase 3 (30-44 weeks)
Proportion of participants achieving remission to normoglycemia at the end of phase 3
Evaluating the proportion of participants achieving remission to normoglycemia (HbA1c \< 6.0% using no antihyperglycemic agents for ≥ 3 consecutive months) at 30-44 weeks follow-up between intervention and control group ( isCGM vs. CBG monitoring, when combined with LCMR and DSME)
Time frame: from enrollment to end of phase 3 (30-44 weeks)
Evaluating the change in HbA1c at the end of phase 3
Evaluating the change in HbA1c (%) at 30-44 weeks follow-up between intervention and control group
Time frame: from enrollment to end of phase 3 (30-42 weeks)
Low Calorie Meal Replacement persistence at the end of Phase 3
Comparing the persistence to Low Calorie Meal Replacement (LCMR) in percentage between the intervention and the control group at the end of phase 3 (30-44 weeks).
Time frame: End of Phase 3 (30-42 weeks)
Proportion of participants initiating/reinitiating antihyperglycemic agents at the end of phase 3
Evaluating the proportion of participants initiating/reinitiating antihyperglycemic agents at the end of phase 3 (30-44 weeks) between the intervention and control group.
Time frame: from enrollment to end of phase 3 ( 30-44 weeks)
Follow-up and change in body weight at the end of phase 3
Evaluating the follow-up and change in body weight (kg) at the end of phase 3 (30-44 weeks) between the intervention and control group
Time frame: from enrollment to end of phase 3 (30-44 weeks)
Follow-up and change in BMI at the end of phase 3
Evaluating the follow-up and change in BMI (kg/m\^2) at the end of phase 3 ( 30-44 weeks) between the intervention and control group
Time frame: from enrollment to end of Phase 3 (30-44 weeks)
Percent weight loss at the end of Phase 3
Evaluating the percent weight loss at the end of Phase 3 (30-44 weeks) between the intervention and control group
Time frame: from enrollment to end of Phase 3 (30-44 weeks)
Follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire status version at the end of Phase 3
Evaluating the follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) between the intervention and control group at the end of phase 3 (30-44 weeks). The DTSQs scale has 8 questions measured on a Likert scale from 6 (very satisfied) to 0 (very dissatisfied) about the participants satisfaction with their diabetes treatment in the last few weeks.
Time frame: from enrollment to end of Phase 3 ( 30-44 weeks)
Follow-up and change in scores in the Diabetes Distress scale (DDS) at the end of phase 3
Evaluating the follow-up and change in scores in the Diabetes Distress scale (DDS) at the end of phase 3 (30-44 weeks) between intervention and control group. The DSS includes 17 questions measured on a Likert scale from 1 (not a problem) to 6 (a very serious problem) about the degree that diabetes has caused the participant distress in the past month. A higher score is reflective of more distress
Time frame: from enrollment to end of Phase 3 (30-44 weeks)
Change in Percent Time in Range (TIR) at the end of Phase 3
Evaluating the change in percent TIR (3.9 to 10.0 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group
Time frame: from enrollment to end of Phase 3 (30-44 weeks)
Change in Percent Tight Time in Range (TITR) at the end of Phase 3
Evaluating the change in percent TITR (3.9 to 7.8 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group
Time frame: enrollment to end of Phase 3 (30-44 weeks)
Change in Percent Time Below Range (TBR) at the end of Phase 3
Evaluating the change in percent TBR (≤ 3.8 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group
Time frame: from enrollment to end of phase 3 (30-44 weeks)
Change in Percent Time Below Range Level 1 at the end of Phase 3
Evaluating the change in percent TBR level 1 hypoglycemia range (3.0 to 3.8 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group
Time frame: from enrollment to end of Phase 3 (30-44 weeks)
Change in Percent Time Below Range Level 2 at the end of Phase 3
Evaluating the change in percent TBR level 2 hypoglycemia range (\< 3.0 mmol/L)at the end of phase 3 (30-44 weeks) from baseline between intervention and control group
Time frame: from enrollment to end of Phase 3 (30-44 weeks)
Change in Percent Time Above Range (TAR) at the end of Phase 3
Evaluating the change in percent TAR (\> 10.0 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group
Time frame: from enrollment to end of Phase 3
Change in mean glucose at the end of Phase 3
Evaluating the change in mean glucose (mmol/L) at the end of phase 3 (30-44 weeks) from baseline between the intervention and control group.
Time frame: from enrollment to end of Phase 3 (30-44 weeks)
Change in Glycemic Variability at the end of Phase 3
Evaluating change in glycemic variability (standard deviation and % coefficient of variation) from baseline to the end of Phase 3 (30-44 weeks) between the intervention and control group.
Time frame: from enrollment to end of Phase 3 (30-44 weeks)
Change in Glucose Management Indicator at the end of Phase 3
Evaluating the change in Glucose management indicator, measured in percentage (%) between the intervention and control group from baseline to the end of Phase 3 (30-44 weeks)
Time frame: from enrollment to end of Phase 3 (30-44 weeks)
Evaluating isCGM metrics at the end of phase 3 between isCGM+ LCMR+ DSME and CBG+ LMCR+ DSME
Evaluating isCGM metrics (collected from a blinded isCGM) between isCGM vs. CBG monitoring, when combined with LCMR and DSME at 30-42 weeks follow-up. We will describe the mean (SD) and/or median (IQR) for TIR and TITR among the pooled sample of participants from both randomized arms (isCGM and CBG) achieving remission to prediabetes or remission to normoglycemia.
Time frame: End of Phase 3 (30-44 weeks)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Mar 2027, 18 months later.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 18 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
LMC Diabetes & Endocrinology Ltd.